Health · 2 views
Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease Risk
(MedPage Today) -- The anti-CD20 agent rituximab was associated with a higher risk of inflammatory bowel disease (IBD) in people with relapsing-remitting multiple sclerosis (MS) compared with other disease-modifying treatments (DMTs), a…
Summary
(MedPage Today) -- The anti-CD20 agent rituximab was associated with a higher risk of inflammatory bowel disease (IBD) in people with relapsing-remitting multiple sclerosis (MS) compared with other disease-modifying treatments (DMTs), a population
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Scientists propose national microbiome plan to prevent chronic diseaseContinue reading
- Study finds patients experienced rapid weight gain after starting antipsychotic medicationContinue reading
- Anxiety builds over Medicaid work requirementsContinue reading
- Calley Means Resigns as Top RFK Jr. AdvisorContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow